SCHEMBL3139065

SCHEMBL3139065

Clc1cncc(-c2ccccn2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.54
▸ CCR1 P32246 3/20 0.54
▸ CCR5 P51681 3/20 0.54
▸ CCR8 P51685 3/20 0.54
▸ LMNA P02545 3/20 0.54
▸ METAP1 P53582 3/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ DOHH Q9BU89 1/20 0.54
▸ P4HTM Q9NXG6 1/20 0.54
▸ L3MBTL1 Q9Y468 4/20 0.52
▸ TDP1 Q9NUW8 3/20 0.52
▸ TP53 P04637 3/20 0.52
▸ ALOX15 P16050 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ ALPL P05186 1/20 0.52
▸ HSP90AA1 P07900 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30472690 1.00 KDM4E (0.54) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL13140367 0.86 KDM4E (0.70) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL23598500 0.82 KDM4E (0.78) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL23598683 0.82 KDM4E (0.78) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL19944117 0.78 KDM4E (0.59) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL27946179 0.78 KDM4E (0.59) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL70338 0.78 KDM4E (0.71) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL29727933 0.78 KDM4E (0.71) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL17463144 0.77 KDM4E (0.54) KDM4ECCR1CCR5CCR8LMNA
SCHEMBL13798855 0.77 KDM4E (0.54) KDM4ECCR1CCR5CCR8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-02-27 — — US disclosed
EP-4452965-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-10-30 — — EP disclosed
WO-2023118253-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-06-29 — — WO disclosed
EP-1742935-B1 POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN INC (US) 2010-02-24 — — EP disclosed
US-7642354-B2 Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine ICAGEN, INC. (US) 2010-01-05 — — US disclosed
EP-1742935-A1 POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-17 — — EP disclosed
WO-2005121126-A1 POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-12-22 — — WO disclosed
US-20050239800-A1 Polycyclic pyrazines as potassium ion channel modulators ICAGEN, INC. (US) 2005-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS LPAR1, LPAR2, LPAR3 KDM4E 2678/4885CCR1 90/4885CCR5 210/4885
US-20050239800-A1 Polycyclic pyrazines as potassium ion channel modulators KCNJ2, KCNH2, KCNJ1 KDM4E 1618/4885CCR1 4835/4885CCR5 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback